Loading
A phase 3 trial of Dexrazoxane, Doxorubicin, Cyclophosphamide, Paclitaxel / nab-paclitaxel, Trastuzumab and Tamoxifen in Inflammatory breast cancer and Breast cancer, run by National Cancer Institute (NCI), recorded as terminated on the registry.
Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer is a phase 3 interventional study registered as NCT00016276 by National Cancer Institute (NCI), with 396 participants recorded, started 2001-05 and due to reach its primary completion in 2005-03. Interventions recorded: dexrazoxane hydrochloride, doxorubicin hydrochloride, cyclophosphamide, paclitaxel, trastuzumab, therapeutic conventional surgery, radiation therapy, tamoxifen citrate, laboratory biomarker analysis. Conditions recorded: Cardiac Toxicity, Inflammatory Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IV Breast Cancer.
Linked to the drug Dexrazoxane because the registry names it among its interventions and Inflammatory breast cancer and Breast cancer among its conditions. Registry record only: no result has been read by an editor.
Shares Trastuzumab, Doxorubicin, Cyclophosphamide, Paclitaxel / nab-paclitaxel and the tag pipeline.
Shares Dexrazoxane, Doxorubicin, Cyclophosphamide and the tag pipeline.
Shares Trastuzumab, Paclitaxel / nab-paclitaxel, Breast cancer (all types) and the tag pipeline.
Shares Tamoxifen, Breast cancer (all types) and the tag pipeline.
Shares Tamoxifen, Breast cancer (all types) and the tag pipeline.
Shares Paclitaxel / nab-paclitaxel, Breast cancer (all types) and the tag pipeline.
Shares Trastuzumab, Cyclophosphamide, Breast cancer (all types) and the tag pipeline.
Shares Tamoxifen, Breast cancer (all types) and the tag pipeline.